Navigation Links
FDA Panel Mulls Ban on Kids' Cold Medicines
Date:10/18/2007

There's no proof they help children under 6, and they may do harm, experts say

THURSDAY, Oct. 18 (HealthDay News) -- Beginning Thursday, a panel of experts at the U.S. Food and Drug Administration will consider banning the sale of over-the-counter cough and cold medicines for young children.

Such a ban already has the support of safety experts at the FDA, who published a 365-page review on the issue in late September. Any recommendation from the advisory panel would apply to decongestant use in children under 2, and antihistamines in those younger than 6. While the FDA does not have to follow a panel's recommendation, it usually does.

According to the FDA safety review, decongestants and antihistamines have been linked with 123 pediatric deaths since 1969.

Many outside experts are also in favor of restricting children's access to cold remedies.

"The panel should recommend that the FDA carefully reevaluate their existing approval of cough and cold preparations being marketed to children under 6," said Dr. Michael Shannon, chief of the Division of Emergency Medicine at Children's Hospital Boston. "Our hope is that they will agree that it is not appropriate to market these products to [these] children."

The products covered in the debate include approximately 800 popular medicines sold in the United States under names such as Toddler's Dimetapp, Triaminic Infant and Little Colds. Experts estimate that Americans spend about $2 billion per year on these types of medications.

Last Thursday, leading drug makers announced a voluntary withdrawal of oral cough and cold medicines marketed for use in infants.

That move affected only infant oral medicines, not those intended and labeled for use in children age 2 and older, Shannon noted. And it comes as U.S. regulators review the products' safety.

Shannon, who filed the original petition with the FDA in March and is testifying at the hearings, doesn't think that last week's recall by manufacturers goes far enough. The recall only affects children under 2 and not children between 2 and 5, who make up two-thirds of those taking the drugs, he said.

"They made an effort, but it was nowhere near far enough," Shannon said.

In addition, these cold products simply don't work, according to Shannon. "There is no reason to give something that costs money, is ineffective and has potential risks," he said.

Not only can these medications be dangerous, but studies have shown that they have no significant effect, the Boston expert said. "One can question what their effectiveness is in older children and even adults," Shannon said. "Across all ages, the scientific evidence for their effectiveness is very weak, and, for children under 6, the data are clear that they don't work."

Linda A. Suydam is president of the Consumer Healthcare Products Association (CHPA), which represents manufacturers of nonprescription medicines. In a statement, she said that, "The reason the makers of over-the-counter oral cough and cold medicines for infants are voluntarily withdrawing these medicines is that there have been rare patterns of misuse leading to overdose recently identified, particularly in infants, and safety is our top priority."

Shannon is also concerned about the safety of these medications. "These drugs interact with other drugs. These drugs have exaggerated effects on children who have other illnesses," he said.

And nothing conquers the common cold, he added.

"We have to accept the fact that there are no real treatments for the cold," Shannon said. "It's a mistake to think that there are medications that are really going to make a cold go away sooner or make the child feel much better," he said. "Medication for fever works, but these medications for cough suppression do not treat the common cold."

Another expert agreed with Shannon. "Colds take a lot of time to nurture, and the medicines don't really speed up that process at all," said Catherine Tom-Revzon, the clinical pharmacy manager at Children's Hospital at Montefiore in New York City.

Tom-Revzon believes that rather than risking potential harm from these medications, it's better to remove them from the market.

For children with colds, Tom-Revzon recommended giving lots of fluids, using a misting humidifier and putting an extra pillow under the child's head to help drain fluids. "If the child has a high fever and doesn't want to eat or drink, something more serious may be going on, and the child should be brought to the doctor," she said.

An FDA review of records filed with the agency between 1969 and September 2006 found 54 reports of deaths in children associated with decongestant medicines made with pseudoephedrine, phenylephrine or ephedrine. It also found 69 reports of deaths associated with antihistamine medicines containing diphenhydramine, brompheniramine or chlorpheniramine.

Most of the deaths involved children younger than 2.

On Sept. 28, the FDA announced that the makers of almost 200 unapproved prescription medicines containing the ingredient hydrocodone must cease making these products for children under 6 by Oct. 31.

Hydrocodone, a narcotic, is commonly used to ease pain and cough. According to The New York Times, many of the children's hydrocodone products currently on the market have been around for decades but never received approval from the modern-day FDA.

More information

For more on cold remedies for children, visit the American Academy of Pediatrics.



SOURCES: Catherine Tom-Revzon, Pharm.D, clinical pharmacy manager, Children's Hospital at Montefiore, New York City; Michael Shannon, M.D., M.P.H., chief, Division of Emergency Medicine, Children's Hospital, Boston; Sept. 28, 2007, The New York Times


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Panel suggests selling allergy drugs OTC
2. FDA panel refuses anti-viral cold remedy
3. Panel to Help Combat HIV/AIDS In Asia-Pacific Region
4. Expert panel confident of making AIIMS fully autonomous
5. Anti-Quota Stir: Resident Docs Demand Experts Panel
6. Circumcision Studies to Continue Says Health Panel
7. Breast Cancer Review Panel Adds Two Experts
8. Shingles Vaccine For Older People - Panel Recommendation
9. Complaints Against US Federal lab Over-ruled by Panel
10. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
11. Generic Biologics – U.S Panel Hearing Draws Mixed Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of a ... go out of their way to be romantic, and may exaggerate a strength or ... any online dating profile. , A recent study from Queendom.com , however, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured ... West Penn Burn Center, part of the Allegheny Health Network, has partnered ... you the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
(Date:2/12/2016)... 12, 2016  SI-BONE, Inc., a medical device company that pioneered ... minimally invasive surgical (MIS) device indicated for fusion for certain disorders ... (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , Minnesota ... York , Rhode Island , ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health System ... Dwight Howard to bring a one-of-a-kind experience to ... Using cutting-edge technologies such as 360-degree video and Google ... virtually, then literally – giving the patients and their ... it was all caught on video . ...
Breaking Medicine Technology: